Eli Lilly's SWOT analysis: stock soars on GLP-1 success, faces competition challenges
Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...
Are Weight-Loss Drugs Like Gym Memberships? The Answer Is Worth Billions
An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.
Healio14h
Increase in online searches for obesity drugs correlates with rise in prescriptions
The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with ...
Eli Lilly Stock's Correction Brings Opportunity
Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.
Everett13h
GLP-1 Weight-loss Drugs Should be Made Affordable for All Americans
The widespread acceptance of the so-called GLP-1 drugs, Zepbound by Eli Lilly and Wegovy by Novo Nordisk, for weight loss has created a game-changing dynamic for the overall health of the 72% of ...
ClearBridge Large Cap Growth ESG Strategy Q4 2024 Commentary
The ClearBridge Large Cap Growth ESG Strategy underperformed its Russell 1000 Growth Index benchmark in the fourth quarter.
STAT16h
Pharmalittle: We’re reading about a Super Bowl ad for compounded obesity drugs, a PEPFAR waiver, and more
A Super Bowl ad for weight loss medications from telehealth company Hims & Hers is optimized to engage and infuriate ...